Home MarketWockhardt Ltd.

Wockhardt Ltd. Stock Info: As on 2018-05-24 15:59:59

Nse

662.30

21.85(3.41%)
Change%
52 Week Range
530.65
22.00
1,012.00
8.00
Open647.60
Day's Range576.41 - 704.50
Value Traded (in ₹ Cr.) 102.48

Bse

664.25

23.60(3.68%)
Change %
52 Week Range
531.50
22.00
1,012.00
8.00
Open645.00
Day's Range576.59 - 704.72
Value Traded (in ₹ Cr.) 8.28

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 81,985,382.00 74.11%
Mutual Funds/UTI 4,057,107.00 3.67%
FII 6,033,358.00 5.45%
Employee 0.00 0.00%
Public 13,626,754.00 12.32%
Government 0.00 0.00%
Others 3,466,315.00 3.13%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 3.46
Basic EPS (Rs.) 12.40
Cash EPS 21.96
BVPerShare Excl 110.31
Operating Revenue 207.85
PBDITPerShare 35.57
Dividend 10.00
NPPerShare 12.40
Current Ratio 1.21
Quick Ratio 0.86
PriceToBV 6.53
Earnings 0.01
PBDIT Margin 17.11
PBT Margin 5.16
NP Margin 5.96
Return On Assets 3.02
Retention Ratios 19.37
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 2,545.83
Total Expenses 2,427.05
EBITDA 393.16
PBT 118.78
PAT 137.12
Net Income 137.12
More
Parameter Mar-18 (₹ Cr.) 6M % change
Total Income 1,470.58
Total Expenses 1,155.23
EBITDA 261.38
PBT 232.19
PAT 144.92
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 356.12
Net worth 1,821.02
Investments 297.22
Total Liability 4,536.85
Total debt 1,340.55
Net block 2,129.85
Total Assets 4,536.85
Parameter Mar-17 (₹ Cr.) 6M % change
Total share capital 353.80
Net worth 1,388.98
Investments 297.22
Total Liability 4,641.03
Total debt 1,716.31
Net block 1,973.06
Total Assets 4,641.03
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21
524.95580

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38
418.5491.2

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
18882036.65
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aarti Drugs Ltd.

530 529.15 0.16
526585

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities -235.02
Cash from investing activities 369.28
Cash from financing activities -133.06
Net change in cash 1.20

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Aditya Birla Sun Life Pure Value Fund 1.73%
Aditya Birla Sun Life Arbitrage Fund 0.56%
L&T Midcap Fund - Regular Plan 0.70%
Reliance Arbitrage Fund 0.23%
HDFC Capital Builder Value Fund - Regular Plan 0.56%
ICICI Prudential Equity - Arbitrage Fund 0.19%

M Venkatesh appointed MRPL MD

M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.

24-05-2018 11:42

TCS expands operations in Florida as part of Transamerica deal

India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.

24-05-2018 11:16

Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April

Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

Kotak India Growth Fund Series 4: change in investment factsheets for April

Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

BLS International to assist Sopra Steria on UK visa renewals

Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.

24-05-2018 10:51

Wockhardt Ltd. - Announcement under Regulation 30 (LODR)-Credit Rating

Disclosure under Regulation 30 of LODR - Update on Credit Rating

15-May-2018 06:54 PM

Wockhardt Ltd. - Credit Rating

Wockhardt Limited has informed the Exchange regarding Credit Rating update under Regulation 30 of LODR

15-May-2018 06:50 PM

Wockhardt Ltd. - Updates

Wockhardt Limited has informed the Exchange regarding ''Newspaper Advertisements confirming completion of dispatch of Notice of Postal Ballot''.

10-May-2018 11:29 AM

Wockhardt Ltd. - Newspaper Advertisements Confirming Completion Of Dispatch Of Notice Of Postal Ballot

Newspaper Advertisements confirming completion of dispatch of Notice of Postal Ballot

10-May-2018 11:16 AM

Wockhardt Ltd. - Shareholders meeting

Wockhardt Limited has informed the Exchange regarding Notice of Postal Ballot

08-May-2018 04:35 PM

Wockhardt Ltd. - Announcement under Regulation 30 (LODR)-Credit Rating

Disclosure under Regulation 30 of LODR - Update on Credit Rating

15-May-2018 06:54 PM

Wockhardt Ltd. - Newspaper Advertisements Confirming Completion Of Dispatch Of Notice Of Postal Ballot

Newspaper Advertisements confirming completion of dispatch of Notice of Postal Ballot

10-May-2018 11:16 AM

Wockhardt Ltd. - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

Notice of Postal Ballot and Postal Ballot Form

08-May-2018 04:19 PM

Corporate Details

About Management

YEAR EVENTS 2000 - Wockhardt has launched cardiac drug enalapril maleate in the US through its marketing joint venture with Sidmak Laboratories. - Pharmaceutical major Wockhardt Ltd has set up a corporate training centre with modern and state-of-the-art facility under one roof at Aurangabad. 2001 - Wockhardt Hospitals Ltd, the wholly owned subsidiary of Wockhardt Ltd, will set up two cardiac hospitals in Mumbai and Bangalore. - The Company has terminated its three-year old marketing alliance with Sidmak Laboratories, one of the top ten generic pharma companies in the US. - Pharma major Wockhardt Ltd. has entered into a strategic alliance with a Japanese firm Eisai Company Ltd. to manufacture and market a neurology drug -- Methycobal. - Wockhardt Hospitals Ltd, the wholly owned subsidiary of pharmaceutical major Wockhardt Ltd, has tied up with four international health insurance companies to offer medical cover to non-resident Indians. - AGM JUNE 8 2001 Wockhardt has launched an innovative and attractive employee stock option scheme, ESOP. - Wockhardt Ltd has introduced an employee stock option (ESOP) scheme for over 175 employees in the senior and middle management levels with about 2,00,000 shares being allotted. 2002 -The Hari L Mundra has joined Wockhardt as vice-chairman. Mundra will spearhead the company's domestic operations which account for 70 per cent of its turnover. - Wockhardt Ltd has appointed Mr. Lalit Kumar as Executive Director on its Corporate Board. Mr. Kumar will spearhead Wockhardt's International Business covering bulk drug operations and formulations export, as well as ANDA research and Intellectual Property Rights. 2003 -Wockhardt restructured its field organization to upgrade its competitiveness and productivity. -Mumbai based wockhardt will hit the domestic market with the first indigenously developed insulin soon, in a move to induce turmoil in the market. -Wockhardt has launched new four speciality hospitals at its Mulund complex in Mumbai. -Maharashtra Government decided to terminate its Joint Venture agreement with Wockhardt for setting up a super speciality hospital. -Wockhardt Limited has acquired CP pharmaceuticals(Holdings) Ltd, along with its subsidiaries. -Wockhardt is strengthening its marketing strategies and distribution system to unveil human insulin in Indian market. -Wockhardt Launched Asia's first human recombinant insulin, making India the first Asian country to develop, manufacture and market the product. -Wockhardt Ltd has received USFDA approval for marketing bethanecol Chloride tablets in the US. -Wockhardt baged USFDA approval for Bethanechol -Baged US approval to sell bethanechol chloride tablets -Wockhardt Ltd has informed that Mr. JS Khorakiwala who has been on the board of the company as Executive Director, has resigned from the directorship with immediate effect. 2004 -Wockhardt Ltd has filed an Investigational New Drug (IND) application for its new drug for respiratory infections, WCK-1152 - Wockhardt Ltd has acquired German pharmaceutical company esparma GmbH for a consideration of $11 million (around Rs 49 crore). -Centre for Drug Evaluation & Research, an arm of the US Food & Drug Administration (US FDA), has approved the sterile injectable facility as well as facilities for sterile bulk drugs (active pharmaceutical ingredient) and formulations spread over three locations in India -Wockhardt gets USFDA nod for 6 manufacturing units 2005 -Launches of India's first automatic insulin delivery device specially designed for the convenience of Indian diabetic patients on February 14, 2005 -Wockhardt forges alliance with Kamineni Group to establish two world-class heart hospitals in the Hyderabad -Wockhardt unveils father`s heart network -Wockhardt receives US FDA approval for marketing cefuroxime axetil in the US market -Wockhardt unveils new generation hepatitis A vaccine -Wockhardt rolls out new Hepatitis A vaccine 2006 -Wockhardt's Waluj plant approved by US FDA 2007 -Wockhardt signs in-licensing pact with Crawford Healthcare of UK. -Wockhardt Ltd has appointed Mr. Rajiv B Gandhi as Director- Finance & Information for a period of five years effective from February 22, 2007, subject to the approval of shareholders. -Wockhardt Ltd has announced US FDA approval for marketing Ketorolac anti-inflammatory injection in the US market, its third US FDA approval in the last ten days. - Wockhardt Ltd on May 03, 2007 has announced the acquisition of Negma Laboratories, the fourth largest independent, integrated pharmaceutical group in France with sales of $ 150 million. The Company has acquired Negma Laboratories in an all-cash deal worth $ 265 million. The transaction is valued at 1.8 times the sales and 9.7 times the EBITDA. 2008 Wockhardt Ltd has unveiled Cetirizine tablets in the US, after having got the regulatory clearance to market different strengths of anti-allergy medicine Cetirizine Hydrochloride. Cetirizine is the generic version of Pfizer's Zyrtec brand and the total market for Cetirizine tablets in the US is $1.4 billion. - Wockhardt Ltd has forayed into a 10- year in-licensing pact with the UK's Sinclair Pharma plc to market dermatology and dental products in India. 2009 -A biotechnology breakthrough in Diabetes Wockhardt launches new insulin (Glaritus) in India. -Harvard Medical School Professor shows connection of Cancer and Heart diseases with Diabetes. -Wockhardt announces its succession plan under the leadership of Chairman Habil Khorakiwala. -Wockhardt launches anti-hypertensive drug Nicardipine injections in USA. -Wockhardt wins Government of India Patent Award. -Wockhardt appoints BDO Haribhakti as auditor. -Wockhardt announces Entacapone patent settlement with Orion Corporation. 2010 -Wockhardt receives US FDA approval for antibacterial Levofloxacin -Wockhardt launches Prostate drug Flomax in the United States on Day-1. -Wockhardt receives US FDA approval for the generic version of Toprol XLr, a cardiac drug. 2011 -Wockhardt launches generic version of Protonixr tablets in the US. -Wockhardt receives US FDA approval for generic version of Effexor XRr capsules. -Wockhardt launches three new products in three weeks, in the United States. -Wockhardt receives tentative US FDA approval for generic version of Patanolr ophthalmic solution. 2012 -Wockhardt launches generic version of anti--ulcer drug Prevacidr. -Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XLr. -Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodonr. -Wockhardt receives US FDA approval for generic version of Parkinson's drug Comtanr. 2013 -Wockhardt receives the 'Best Enterprise' award from the Europe. -Wockhardt launches generic version of anti-convulsant drug Lamictal XR. 2014 -Wockhardt's drug discovery gets a boost with fast track approval by USFDA. 2015 -Wockhardt Receives ANDA Approval for pain medication Oxycodone liquid -Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt 2015 -Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -Wockhardt receives ANDA approval for pain medication Oxycodone liquid -Wockhardt gains over 2% after MHRA completes plant inspection -Wockhardt gets QIDP status for new antibiotic from US FDA.

Registered Office

PO Barotiwala,

01795-664444,,,      01795-664312,

Registrar Details

Link Intime India Pvt. Ltd.